John Wilding

Has grant

Professor of Medicine

University of Liverpool

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

How are treatment outcomes for people with severe obesity ImPROved by GROUP-based behavioural intervention?

Open Date: 2021-05-01

Close Date: 2026-04-30

Grant: Close

Type 2 Diabetes (T2D) in 16 – 40 year olds: A Multifactorial Management Intervention to Address Multimorbidity in Early-Onset T2D in Adults (The M3 Research Programme)

Open Date: 2021-03-01

Close Date: 2026-02-28

Grant: Close

MECNUT: Impact of dietary exposure to emulsifiers on the intestinal mucosa - implications for inflammatory bowel disease and metabolic syndrome

Open Date: 2017-11-01

Close Date: 2021-03-30

Grant: Close

Patients' expectations, beliefs and attitudes towards glucose-lowering drugs and their effects on body weight in Type 2 diabetes: a prospective study and pilot intervention.

Open Date: 2011-09-01

Close Date: 2014-08-31

Grant: Close

Benefits of weight loss in obese patients with asthma: mechanical or immunological mechanisms?

Open Date: 2004-10-01

Close Date: 2008-12-31

Articles (20)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (11)

Jason Christian Grovenor Halford

University of Leeds

UNITED KINGDOM

View details

Timothy Jackson

King’s College London

UNITED KINGDOM

View details

Rachel Batterham

University College London

UNITED KINGDOM

View details

Gary A Wittert

AUSTRALIA

View details

Francesco Giorgino

ITALY

View details

Kirsi Pietiläinen

Professor in Clinical Metabolism

University of Helsinki

FINLAND

View details

Sizheng Steven Zhao

The University of Manchester

UNITED KINGDOM

View details

Francisco Lopez-Jimenez

UNITED STATES

View details

Emanuele Di Angelantonio

University of Cambridge

UNITED KINGDOM

View details

Roy Taylor

Professor of Medicine and Metabolism; Magnetic Resonance Centre

Newcastle University

UNITED KINGDOM

View details

Carel Le Roux

Professor

University College Dublin College of Health Sciences

IRELAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

John Wilding

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (20)

Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation

Risk of diabetic retinopathy and diabetic macular oedema with sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database

Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.

1896-LB: Clinical Features and C-Peptide Levels Associated with Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Dapagliflozin vs. Placebo—Insights from DECLARE-TIMI 58

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

The double burden of malnutrition in individuals: Identifying key challenges and re-thinking research focus.

Obesity pharmacotherapy in older adults: a narrative review of evidence.

SGLT2 Inhibitors - The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.

New insights into the treatment of obesity

Adipocytes in obesity: A perfect reservoir for SARS-CoV-2?

Association of Cardiac Biomarkers with Major Adverse Cardiovascular Events in High-risk Patients with Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Diazoxide Choline Extended-Release Tablet in People With Prader-Willi Syndrome: A Double-Blind, Placebo-Controlled Trial

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE)

Obesity: medical management

Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation

Collaborators (11)

Jason Christian Grovenor Halford

Timothy Jackson

Rachel Batterham

Gary A Wittert

Francesco Giorgino

Kirsi Pietiläinen

Sizheng Steven Zhao

Francisco Lopez-Jimenez

Emanuele Di Angelantonio

Roy Taylor

Carel Le Roux

Make your next move.